Pain reactivity in 2-month-old infants after prenatal and postnatal selective serotonin reuptake inhibitor medication exposure

Pediatrics

Volumn 115, Issue 2, 2005, Pages 411-425

  Oberlander, Tim F ^a   Grunau, Ruth Eckstein ^a   Fitzgerald, Colleen ^a   Papsdorf, Michael ^c   Rurak, Dan ^b   Riggs, Wayne ^c  

^a Centre for Community Child Health Research   (Canada)

^b CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Infant pain; Prenatal drug effects; Prenatal SSRI exposure

Indexed keywords

ANTIDEPRESSANT AGENT; CLONAZEPAM; FLUOXETINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; BEHAVIOR; BREAST MILK; BREATHING; CHILD BEHAVIOR; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FACIAL EXPRESSION; FEMALE; HEART RATE; HEART RATE VARIABILITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MODULATION; NEWBORN; NEWBORN PERIOD; NOCICEPTIVE STIMULATION; PAIN; PERINATAL DRUG EXPOSURE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; SAMPLE SIZE; CASE CONTROL STUDY; CHILD DEVELOPMENT; DRUG EFFECT; ENVIRONMENTAL EXPOSURE; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PREGNANCY COMPLICATION;

ADULT; CASE-CONTROL STUDIES; CHILD DEVELOPMENT; DEPRESSIVE DISORDER; FEMALE; HEART RATE; HUMANS; INFANT; INFANT BEHAVIOR; MATERNAL EXPOSURE; PAIN; PAIN MEASUREMENT; PREGNANCY; PREGNANCY COMPLICATIONS; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 17644392473     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-0420     Document Type: Article

References (125)

1. Kim J, Misri S, Kent N, Oberlander T, Rurak DW, Riggs KW. Comparison of fetal and neonatal fluoxetine and paroxetine exposure during the perinatal period in humans. Presented at: the Annual Meeting of the American Association of Pharmaceutical Scientists; November 14-18, 1999; New Orleans, LA
2. Misri S, Kim J, Riggs KW, Kostaras X. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry. 2000;61:828-832
3. Misri S, Kostaras D, Kostaras X. The use of selective serotonin reuptake inhibitors during pregnancy and lactation: current knowledge. Can J Psychiatry. 2000;45:285-287
4. Oberlander TF, Eckstein GR, Fitzgerald C, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res. 2002;51:443-453
5. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336:258-262
6. Koren G, Nulman I, Addis A. Outcome of children exposed in utero to fluoxetine: a critical review. Depress Anxiety. 1998;8(suppl 1):27-31
7. Kulin NA, Pastuszak A, Koren G. Are the new SSRIs safe for pregnant women? Can Fam Physician. 1998;44:2081-2083
8. Yoshida K, Smith B, Craggs M, Kumar RC. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry. 1998;172:175-178
9. Yoshida K, Smith B, Kumar RC. Fluvoxamine in breast-milk and infant development. Br J Clin Pharmacol. 1997;44:210-211
10. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry. 2003;60:720-726
11. Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry. 1997;154:1255-1260
12. Vendittelli F, Alain J, Nouaille Y, Brosset A, Tabaste JL. Case of lipomeningocele reported with fluoxetine (and alprazolam, vitamins B1 and B6, heptaminol) prescribed during pregnancy. Eur J Obstet Gynecol Reprod Biol. 1995;58:85-86
13. Stanford MS, Patton JH. In utero exposure to fluoxetine HCl increases hematoma frequency at birth. Pharmacol Biochem Behav. 1993;45:959-962
14. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001;158:1728-1730
15. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA. 1993;269:2246-2248
16. Kent LS, Laidlaw JD. Suspected congenital sertraline dependence. Br J Psychiatry. 1995;167:412-413
17. Spencer MJ. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics. 1993;92:721-722
18. Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry. 1993;32:1253-1255
19. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr. 2001;90:288-291
20. Oberlander T, Misri S, Fitzgerald C, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. Clin J Psychiatry. 2004;65:230-237
21. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry. 2000;48:996-1000
22. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med. 1996;335:1010-1015
23. Chambers CD, Anderson PO, Thomas RG, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics. 1999;104(5). Available at: www.pediatrics.org/cgi/content/ful/104/5/e61
24. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med. 2002;156:1129-1132
25. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics. 2004;113:368-375
26. Loebstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. J Psychiatry Neurosci. 1997;22:192-196
27. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry. 2002;159:1889-1895
28. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E. The use of psychotropic medications during breast-feeding. Am J Psychiatry. 2001;158:1001-1009
29. Hale TW, Shum S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr (Phila). 2001;40:681-684
30. Ohman R, Hagg S, Carleborg L, Spigset O. Excretion of paroxetine into breast milk. J Clin Psychiatry. 1999;60:519-523
31. Piontek CM, Wisner KL, Perel JM, Peindl KS. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry. 2001;62:111-113
32. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther. 2002;72:184-191
33. Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51:215-235
34. Fitzgerald M. Pain in Infancy. In: Dickenson AH, Besson H. Appleton J-MR, Berlin I, eds . Pharmacology of Pain. New York, NY: Springer; 1997:447-465
35. Fitzgerald M. Pain in infancy: some unanswered questions. Pain Rev. 1995;2:77-91
36. Waagepetersen HS, Sonnewald U, Schousboe A. GABA paradox: multiple roles as metabolite, neurotransmitter, and neurodifferentiative agent. J Neurochem. 1999;73:1335-1342
37. Sawynok J, Reid A. Interactions of descending serotonergic systems with other neurotransmitters in the modulation of nociception. Behav Brain Res. 1996;73:63-68
38. Whitaker-Azmitia PM, Druse M, Walker P, Lauder JM. Serotonin as a developmental signal. Behav Brain Res. 1996;73:19-29
39. Lauer JA, Adams PM, Johnson KM. Perinatal diazepam exposure: behavioral and neurochemical consequences. Neurotoxicol Teratol. 1987;9:213-219
40. Huether G, Thomke F, Adler L. Administration of tryptophan-enriched diets to pregnant rats retards the development of the serotonergic system in their offspring. Brain Res Dev Brain Res. 1992;68:175-181
41. Lauder JM. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci. 1993;16:233-240
42. Di Pasquale E, Monteau R, Hilaire G. Endogenous serotonin modulates the fetal respiratory rhythm: an in vitro study in the rat. Brain Res Dev Brain Res. 1994;80:222-232
43. Smith D, Gallager D. GABA, benzodiazepine and serotonergic receptor development in the dorsal raphe nucleus: electrophysiological studies. Brain Res. 1987;432:191-198
44. Lauder JM, Han VK, Henderson P, Verdoorn T, Towle AC. Prenatal ontogeny of the GABAergic system in the rat brain: an immunocytochemical study. Neuroscience. 1986;19:465-493
45. Prechtl HF. The behavioural states of the newborn infant: a review. Brain Res. 1974;76:185-212
46. Hamilton M. Rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62
47. Grunau RV, Craig KD. Pain expression in neonates: facial action and cry. Pain. 1987;28:395-410
48. Grunau RV, Johnston CC, Craig KD. Neonatal facial and cry responses to invasive and non-invasive procedures. Pain. 1990;42:295-305
49. Craig KD, Whitfield MF, Grunau RV, Linton J, Hadjistavropoulos HD. Pain in the preterm neonate: behavioural and physiological indices. Pain. 1993;52:287-299
50. Grunau RE, Oberlander T, Holsti L, Whitfield MF. Bedside application of the Neonatal Facial Coding System in pain assessment of premature neonates. Pain. 1998;76:277-286
51. Grunau RVE, Craig KD. Facial activity as a measure of neonatal pain expression. In: Tyler DC, Krane EJ, eds. Advances in Pain Research and Therapy. New York, NY: Raven Press Ltd; 1990:147-155
52. Lilley CM, Craig KD, Grunau RE. Expression of pain in infants and toddlers: developmental changes in facial action. Pain. 1997;72:161-170
53. Saul JP, Berger RD, Albrecht P, Stein SP, Chen MH, Cohen RJ. Transfer function analysis of the circulation: unique insights into cardiovascular regulation. Am J Physiol. 1991;261:H1231-H1245
54. Fox NA, Porges SW. The relation between neonatal heart period patterns and developmental outcome. Child Dev. 1985;56:28-37
55. Porter FL, Porges SW, Marshall RE. Newborn pain cries and vagal tone: parallel changes in response to circumcision. Child Dev. 1988;59:495-505
56. Litvack DA, Oberlander TF, Carney LH, Saul JP. Time and frequency domain methods for heart rate variability analysis: a methodological comparison. Psychophysiology. 1995;32:492-504
57. Porges SW. Vagal tone: a physiologic marker of stress vulnerability. Pediatrics. 1992;90:498-504
58. Porges SW, Bohrer RE. Analyses of periodic processes in psychophysiological research. In: Cacioppo JT, Tassinary LG. Principles of Psychophysiology: Physical, Social, and Inferential Elements. New York, NY: Cambridge University Press;1990:708-753
59. Oberlander TF, Saul JP. Methodological considerations for the use of heart rate variability as a measure of pain reactivity in vulnerable infants. Clin Perinatol. 2002;29:427-443
60. Gunnar MR, Porter FL, Wolf CM, Rigatuso J, Larson MC. Neonatal stress reactivity: predictions to later emotional temperament. Child Dev. 1995;66:1-13
61. Fox NA. Infant response to frustrating and mildly stressful events: a positive look at anger in the first year. New Dir Child Dev. 1989;47-64
62. Stifter CA, Fox NA. Infant reactivity: physiological correlates of newborn and 5-month temperament. Devl Psychol 1990;26:582-588
63. Doussard-Roosevelt JA, Porges SW, Scanlon JW, Alemi B, Scanlon KB. Vagal regulation of heart rate in the prediction of developmental outcome for very low birth weight preterm infants. Child Dev. 1997;68:173-186
64. DiPietro JA, Porges SW. Vagal responsiveness to gavage feeding as an index of preterm status. Pediatr Res. 1991;29:231-236
65. Oberlander TF, Berde CB, Lam KH, Rappaport LA, Saul JP. Infants tolerate spinal anesthesia with minimal overall autonomic changes: analysis of heart rate variability in former premature infants undergoing hernia repair. Anesth Analg. 1995;80:20-27
66. Oberlander TF, Berde CB, Saul JP. Halothane and cardiac autonomic control in infants: assessment with quantitative respiratory sinus arrhythmia. Pediatr Res. 1996;40:710-717
67. Hanna BD, Saul JP, Cohen RJ, et al. Transfer-function analysis of respiratory sinus arrhythmia-developmental-changes in sleeping premature-infants. Circulation. 1990;82:334-334
68. Oberlander TF, Robeson P, Ward V, et al. Prenatal and breast milk morphine exposure following maternal intrathecal morphine treatment. J Hum Lact. 2000;16:137-142
69. HRV Software [computer program]. Version 2.0. Boston, MA: Boston Medical Technologies; 1995
70. Berger RD, Saul JP, Cohen RJ. Transfer function analysis of autonomic regulation, I: canine atrial rate response. Am J Physiol. 1989;256:H142-H152
71. Oberlander TF, Grunau RE, Whitfield MF, Fitzgerald C, Pitfield S, Saul JP. Biobehavioral pain responses in former extremely low birth weight infants at four months' corrected age. Pediatrics. 2000;105(1). Available at: www.pediatrics.org/cgi/content/full/105/e6
72. Kim J, Axelson JE, Kerns GL, et al. Stereoselective determination of fluoxetine and norfluoxetine by gas chromatography with mass selective detection. Pharm Res. 1995;12:
73. Kim J, Riggs KW, Kim Y, et al. Determination of paroxetine (Paxil) in human serum and milk by gas chromatography/mass spectrometry. Pharm Res. 1997;14:
74. Llabre MM, Spitzer SB, Saab PG, et al. The reliability and specificity of delta versus residualized change as measures of cardiovascular reactivity to behavioral challenges. Psychophysiology. 1991;28:701-711
75. Hains BC, Everhart AW, Fullwood SD, Hulsebosch CE. Changes in serotonin, serotonin transporter expression, and serotonin denervation supersensitivity: involvement in chronic central pain after spinal hemisection in the rat. Exp Neurol. 2002;175:347-362
76. Schreiber S, Backer MM, Yanai J, Pick CG. The antinociceptive effect of fluvoxamine. Eur Neuropsychopharmacol. 1996;6:281-284
77. Nemoto H, Toda H, Nakajima T, et al. Fluvoxamine modulates pain sensation and affective processing of pain in human brain. Neuroreport. 2003;14:791-797
78. de Montigny C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry. 1990;51(suppl B):4-8
79. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11-28
80. Goodnick PJ, Goldstein BJ. Selective serotonin reuptake inhibitors in affective disorders, I: basic pharmacology. J Psychopharmacol. 1998;12(suppl B):S5-S20
81. Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk. J Clin Pharmacol. 1996;36:42-47
82. Velez LI, Shepherd G, Roth BA, Benitez FL. Serotonin syndrome with elevated paroxetine concentrations. Ann Pharmacother. 2004;38:269-272
83. Graudins A, Vossler C, Wang R. Fluoxetine-induced cardiotoxicity with response to bicarbonate therapy. Am J Emerg Med. 1997;15:501-503
84. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41:1247-1266
85. Rasmussen BB, Brosen K. Is therapeutic drug monitoring a case of optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors? Ther Drug Monit. 2000;22:143-154
86. Epperson CN, Jatlow PI, Czarkowski K, Anderson GM. Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs. Pediatrics. 2003;112(5). Available at: www.pediatrics.org/cgi/content/full/112/5/e425
87. Mayes LC, Grillon C, Granger R, Schottenfeld R. Regulation of arousal and attention in preschool children exposed to cocaine prenatally. Ann N Y Acad Sci. 1998;846:126-143
88. Xu Y, Sari Y, Zhou FC. Selective serotonin reuptake inhibitor disrupts organization of thalamocortical somatosensory barrels during development. Brain Res Dev Brain Res. 2004;150:151-161
89. Vorhees CV, Acuff-Smith KD, Schilling MA, Fisher JE, Moran MS, Buelke-Sam J. Developmental neurotoxicity evaluation of the effects of prenatal exposure to fluoxetine in rats. Fundam Appl Toxicol. 1994;23:194-205
90. de Ceballos ML, Benedi A, Urdin C, Del Rio J. Prenatal exposure of rats to antidepressant drugs down-regulates beta-adrenoceptors and 5-HT2 receptors in cerebral cortex: lack of correlation between 5-HT2 receptors and serotonin-mediated behaviour. Neuropharmacology. 1985;24:947-952
91. Cabrera TM, Battaglia G. Delayed decreases in brain 5-hydroxytryptamine 2A/2C receptor density and function in male rat progeny following prenatal fluoxetine. J Pharmacol Exp Ther. 1994;269:637-645
92. Montero D, de Ceballos ML, Del Rio J. Down-regulation of 3Himipramine binding sites in rat cerebral cortex after prenatal exposure to antidepressants. Life Sci. 1990;46:1619-1626
93. Cabrera-Vera TM, Battaglia G. Prenatal exposure to fluoxetine (Prozac) produces site-specific and age-dependent alterations in brain serotonin transporters in rat progeny: evidence from autoradiographic studies. J Pharmacol Exp Ther. 1998;286:1474-1481
94. Cabrera-Vera TM, Garcia F, Pinto W, Battaglia G. Effect of prenatal fluoxetine (Prozac) exposure on brain serotonin neurons in prepubescent and adult male rat offspring. J Pharmacol Exp Ther. 1997;280:138-145
95. Lauder JM, Liu J, Grayson DR. In utero exposure to serotonergic drugs alters neonatal expression of 5-HT(1A) receptor transcripts: a quantitative RT-PCR study. Int J Dev Neurosci. 2000;18:171-176
96. Morrison JL, Chien C, Gruber N, Rurak D, Riggs W. Fetal behavioural state changes following maternal fluoxetine infusion in sheep. Brain Res Dev Brain Res. 2001;131:47-56
97. Nicholson AN, Pascoe PA. Studies on the modulation of the sleepwakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacology. 1988;27:597-602
98. Rayburn WF, Gonzalez CL, Christensen HD, Kupiec TC, Jacobsen JA, Stewart JD. Effect of antenatal exposure to paroxetine (Paxil) on growth and physical maturation of mice offspring. J Matern Fetal Med. 2000;9:136-141
99. Christensen HD, Rayburn WF, Gonzalez CL. Chronic prenatal exposure to paroxetine (Paxil) and cognitive development of mice offspring. Neurotoxicol Teratol. 2000;22:733-739
100. Butkevich IP, Vershinina EA. Maternal stress differently alters nociceptive behaviors in the formalin test in adult female and male rats. Brain Res. 2003;961:159-165
101. Butkevich IP, Khozhai LI, Mikhailenko VA, Otellin VA. Decreased serotonin level during pregnancy alters morphological and functional characteristics of tonic nociceptive system in juvenile offspring of the rat. Reprod Biol Endocrinol. 2003;1:96
102. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry. 2002;159:2055-2061
103. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr. 2003;142:402-408
104. Grunau RE. Long-term consequences of pain in human neonates. In: Anand KJS, Stevens B, McGrath P, eds. Pain in Neonates. 2nd ed. Amsterdam, Netherlands: Elsevier Science; 2000:55-76
105. Dahl RE. The regulation of sleep and arousal: development and psychopathology. Dev Psychopathol. 1996;8:3-27
106. Monk C. Stress and mood disorders during pregnancy: implications for child development. Psychiatr Q. 2001;72:347-357
107. Dahl ML, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry. 1997;171:391-392
108. Rothbart MK, Ahadi SA. Temperament and the development of personality. J Abnorm Psychol. 1994;103:55-66
109. Mayes LC, Bornstein MH. Attention regulation in infants born at risk. In: Burack JA, Enns JT, eds. Attention, Development, and Psychopathology. New York, NY: Guilford Press; 1997:97-122
110. Zhang Y, Raap DK, Garcia F, et al. Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats. Brain Res. 2000;855:58-66
111. Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary- adrenocortical regulation. Endocr Rev. 1996;17:187-205
112. Goodman SH, Gotlib IH. Risk for psychopathology in the children of depressed mothers: a developmental model for understanding mechanisms of transmission. Psychol Rev. 1999;106:458-490
113. Tronick, EZ, Weinberg, MK. Depressed mothers and infants: failure to form dyadic states of consciousness. In: Murray L, Cooper PJ, eds. Postpartum Depression and Child Development. New York, NY: Guilford Press; 1997:54-81
114. Gable S, Isabella R. Maternal contributions to infant regulation of arousal. Infant Behav Dev. 1992;15:95-107
115. Schneider ML, Roughton EC, Koehler AJ, Lubach GR. Growth and development following prenatal stress exposure in primates: an examination of ontogenetic vulnerability. Child Dev. 1999;70:263-274
116. Weinberg MK, Tronick EZ. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry. 1998;59:53-61
117. Newton RW, Hunt LP. Psychosocial stress in pregnancy and its relation to low birth weight. Br Med J (Clin Res Ed). 1984;288:1191-1194
118. Pagel MD, Smilkstein G, Regen H, Montano D. Psychosocial influences on new born outcomes: a controlled prospective study. Soc Sci Med. 1990;30:597-604
119. Parker SJ, Barrett DE. Maternal type A behavior during pregnancy, neonatal crying, and early infant temperament: do type A women have type A babies? Pediatrics. 1992;89:474-479
120. Ponirakis A, Susman EJ, Stifter CA. Negative emotionality and cortisol during adolescent pregnancy and its effects on infant health and autonomic nervous system reactivity. Dev Psychobiol. 1998;33:163-174
121. Abrams SM, Field T, Scafidi F, et al. Newborns of depressed mothers. Infant Ment Health J. 1995;16:233-239
122. DiPietro JA, Hodgson DM, Costigan KA, Hilton SC, Johnson TR. Development of fetal movement-fetal heart rate coupling from 20 weeks through term. Early Hum Dev. 1996;44:139-151
123. Monk C, Fifer WP, Myers MM, Sloan RP, Trien L, Hurtado A. Maternal stress responses and anxiety during pregnancy: effects on fetal heart rate. Dev Psychobiol. 2000;36:67-77
124. Reebye P, Morison SJ, Panikkar H, et al. Affect expression in prenatally psychotropic exposed and nonexposed mother-infant dyads. Infant Ment Health J. 2002;23:403-416
125. Lamberg L. Safety of antidepressant use in pregnant and nursing women. JAMA. 1999;282:222-223